Our results and promising antitumor activity in preclinical models and trials indicate that IL-13Rα2 expression is an important prognostic biomarker of ACC disease outcome and a promising target for therapeutic treatment of ACC. This evidence concerns the gene IL13RA2 and adrenal cortex carcinoma.